Eli Lilly Strengthens Position in $150B Obesity Drug Competition Amid Novo and Pfizer Rivalry — Potential Benefits for ETFs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Source: Benzinga
Healthcare ETFs Capitalizing on Obesity Drug Boom: Healthcare ETFs are benefiting from the $150 billion obesity-drug market, with major players like Eli Lilly, Novo Nordisk, and Pfizer competing for market share, leading to increased investor interest in diversified ETFs.
Eli Lilly's Strong Performance: Eli Lilly's stock rose nearly 5% following impressive third-quarter earnings, prompting a raised profit forecast, while its significant presence in major healthcare ETFs like XLV and IHE highlights its dominance in the sector.
Novo Nordisk's Strategic Moves: Novo Nordisk is making headlines with a $6.5 billion counterbid for biotech Metsera, which is developing innovative weight-loss treatments, intensifying competition in the GLP-1 market against Pfizer's earlier bid.
Emergence of Themed ETFs: The Roundhill GLP-1 & Weight Loss ETF offers a focused investment opportunity in companies leading the anti-obesity trend, reflecting the growing interest in specialized funds within the pharmaceutical landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.950
Low
24.00
Averages
28.56
High
35.00
Current: 25.950
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's Future Investments and Dividend Analysis
- Dividend Yield: Pfizer's recent dividend yield of 6.7% not only provides investors with a steady cash flow but also attracts long-term investors seeking income, thereby enhancing market interest in its stock.
- Analyst Rating Discrepancies: MarketWatch tracked 28 analyst ratings for Pfizer, with 9 recommending 'buy', 15 suggesting 'hold', and 3 advising 'sell', indicating a cautious market sentiment and an overall consensus to 'hold', reflecting uncertainty about future performance.
- R&D Pipeline Progress: Pfizer has 96 drugs in development, with 31 in late-stage trials, particularly the Mevpro-1 phase 3 trial for metastatic castration-resistant prostate cancer, with results expected in the second half of 2026, which could yield an upside of about $2 per share if successful, showcasing Pfizer's strategic focus in oncology.
- Acquisition and Growth Potential: By acquiring companies like Metsera to bolster its GLP-1 drug development, Pfizer is addressing upcoming patent expirations; despite current challenges, its diverse growth catalysts and robust R&D pipeline support future business growth, highlighting its potential in the weight-loss drug market.
See More
Pfizer Faces Patent Expirations and High Dividend Risks
- Patent Expiration Impact: Pfizer's cardiology drugs Eliquis and Vyndaqel are set to lose patent protection in 2028, which is expected to lead to significant revenue declines, exacerbating market pessimism and potentially affecting stock performance.
- Dividend Payment Capability: Despite a high dividend yield of 6.6%, Pfizer's cash flow to dividend ratio hovers around 100%, indicating that the company can utilize cash flow or debt to support dividend payments, although a payout ratio exceeding 100% raises investor concerns.
- Market Comparison Advantage: Pfizer's dividend yield is six times that of the S&P 500 index and significantly higher than the average yields of other pharmaceutical and healthcare companies, providing an attractive proposition for long-term investors despite inherent risks.
- Board Decision Authority: Pfizer's board will ultimately decide on dividend payments, with management signaling support for the dividend; historically, dividends tend to recover quickly after cuts, suggesting potential benefits for long-term investors.
See More
Pfizer Offers 6.6% Dividend Yield Amid Patent Expirations
- Dividend Yield Advantage: Pfizer currently offers a 6.6% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical industry's average of 1.7%, making it attractive to yield-seeking investors despite the risks associated with patent expirations.
- Patent Expiration Risks: Pfizer's cardiology drugs, Eliquis and Vyndaqel, are set to lose patent protection in 2028, which is expected to pressure revenues; while this is common in the pharmaceutical sector, the lack of major new drugs may hinder long-term growth prospects.
- Cash Flow Supports Dividends: Although Pfizer's payout ratio exceeds 100% at 130%, its cash flow payout ratio hovers around 100%, indicating that the company can utilize cash flow or debt to support dividend payments, alleviating investor concerns about dividend sustainability.
- Long-Term Investment Potential: As one of the most influential healthcare companies globally with over a century of success, Pfizer's short-term challenges may not derail its long-term prospects, making it a potentially worthwhile risk for long-term investors seeking dividends and price appreciation.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk, which highlights its strong competitive position in the rapidly growing healthcare sector, with the market expected to reach $100 billion in value by the next decade.
- Breakthrough in Drug Development: Lilly's new candidate, retatrutide, demonstrated impressive results in a phase 3 trial, with the highest dose helping patients lose an average of 28% of their body weight over 80 weeks, and 45% of participants losing more than 30%, indicating its potential to outperform existing products.
- Multiple Mechanism of Action: Retatrutide acts on three hormonal pathways related to appetite and blood sugar management, while Novo Nordisk's drugs target only one pathway, suggesting that retatrutide may offer greater weight loss potential and could become a new favorite in the market.
- Future Market Outlook: With retatrutide's strong efficacy and safety profile, Lilly is poised to apply for regulatory approval in the coming years, further solidifying its market position and potentially delivering high returns for investors as the value of the weight loss drug market continues to rise.
See More
Pfizer Analyst Ratings and Future Outlook
- Divergent Analyst Ratings: MarketWatch tracked 28 ratings for Pfizer (PFE), with 9 analysts recommending a 'buy', 1 suggesting overweight, 15 advising 'hold', and 3 indicating 'sell', indicating a consensus to hold the stock.
- Price Target Increase: Guggenheim Securities reaffirmed its buy rating for Pfizer with a price target of $36 per share, which is 38% higher than the current share price of about $26, reflecting analysts' optimistic outlook on Pfizer's future performance.
- Pipeline Potential: Pfizer has 96 drugs in development, with 31 in late-stage phase 3 trials; analyst Vamil Divan expressed optimism about encouraging results from late-stage trials, predicting a potential upside of about $2 per share if successful.
- Strong Financial Performance: Pfizer's first-quarter report indicated a 22% year-over-year operational revenue growth, with CFO David Denton expressing satisfaction, while CEO Albert Bourla highlighted positive advancements in oncology and obesity within the R&D pipeline, showcasing the company's future growth potential.
See More
Eli Lilly's Breakthrough Weight Loss Drug Trial Success
- Market Share Leadership: Eli Lilly has captured a 60% share of the U.S. GLP-1 market, surpassing early leader Novo Nordisk by launching the dual agonist tirzepatide (Mounjaro and Zepbound), demonstrating its competitive edge in the rapidly growing weight loss drug sector.
- Clinical Trial Success: Lilly's new candidate retatrutide showed remarkable results in a phase 3 trial, with patients losing an average of 28% of their body weight over 80 weeks, and over 30% of participants losing more than 30%, indicating its potential as a more effective weight loss solution compared to existing products.
- Safety and Compliance: The lowest dose of retatrutide had a discontinuation rate of 4.1%, lower than the placebo rate of 4.9%, suggesting that its side effects align with those of current GLP-1 drugs, which may enhance patient adherence and strengthen market competitiveness.
- Future Market Potential: With the weight loss drug market projected to reach $100 billion in the next decade, this breakthrough medication positions Eli Lilly to potentially deliver another blockbuster product, further solidifying its leadership in the field and generating high returns for investors.
See More
Pfizer's Future Investments and Dividend Analysis
- Dividend Yield: Pfizer's recent dividend yield of 6.7% not only provides investors with a steady cash flow but also attracts long-term investors seeking income, thereby enhancing market interest in its stock.
- Analyst Rating Discrepancies: MarketWatch tracked 28 analyst ratings for Pfizer, with 9 recommending 'buy', 15 suggesting 'hold', and 3 advising 'sell', indicating a cautious market sentiment and an overall consensus to 'hold', reflecting uncertainty about future performance.
- R&D Pipeline Progress: Pfizer has 96 drugs in development, with 31 in late-stage trials, particularly the Mevpro-1 phase 3 trial for metastatic castration-resistant prostate cancer, with results expected in the second half of 2026, which could yield an upside of about $2 per share if successful, showcasing Pfizer's strategic focus in oncology.
- Acquisition and Growth Potential: By acquiring companies like Metsera to bolster its GLP-1 drug development, Pfizer is addressing upcoming patent expirations; despite current challenges, its diverse growth catalysts and robust R&D pipeline support future business growth, highlighting its potential in the weight-loss drug market.
See More
Pfizer Faces Patent Expirations and High Dividend Risks
- Patent Expiration Impact: Pfizer's cardiology drugs Eliquis and Vyndaqel are set to lose patent protection in 2028, which is expected to lead to significant revenue declines, exacerbating market pessimism and potentially affecting stock performance.
- Dividend Payment Capability: Despite a high dividend yield of 6.6%, Pfizer's cash flow to dividend ratio hovers around 100%, indicating that the company can utilize cash flow or debt to support dividend payments, although a payout ratio exceeding 100% raises investor concerns.
- Market Comparison Advantage: Pfizer's dividend yield is six times that of the S&P 500 index and significantly higher than the average yields of other pharmaceutical and healthcare companies, providing an attractive proposition for long-term investors despite inherent risks.
- Board Decision Authority: Pfizer's board will ultimately decide on dividend payments, with management signaling support for the dividend; historically, dividends tend to recover quickly after cuts, suggesting potential benefits for long-term investors.
See More
Pfizer Offers 6.6% Dividend Yield Amid Patent Expirations
- Dividend Yield Advantage: Pfizer currently offers a 6.6% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical industry's average of 1.7%, making it attractive to yield-seeking investors despite the risks associated with patent expirations.
- Patent Expiration Risks: Pfizer's cardiology drugs, Eliquis and Vyndaqel, are set to lose patent protection in 2028, which is expected to pressure revenues; while this is common in the pharmaceutical sector, the lack of major new drugs may hinder long-term growth prospects.
- Cash Flow Supports Dividends: Although Pfizer's payout ratio exceeds 100% at 130%, its cash flow payout ratio hovers around 100%, indicating that the company can utilize cash flow or debt to support dividend payments, alleviating investor concerns about dividend sustainability.
- Long-Term Investment Potential: As one of the most influential healthcare companies globally with over a century of success, Pfizer's short-term challenges may not derail its long-term prospects, making it a potentially worthwhile risk for long-term investors seeking dividends and price appreciation.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk, which highlights its strong competitive position in the rapidly growing healthcare sector, with the market expected to reach $100 billion in value by the next decade.
- Breakthrough in Drug Development: Lilly's new candidate, retatrutide, demonstrated impressive results in a phase 3 trial, with the highest dose helping patients lose an average of 28% of their body weight over 80 weeks, and 45% of participants losing more than 30%, indicating its potential to outperform existing products.
- Multiple Mechanism of Action: Retatrutide acts on three hormonal pathways related to appetite and blood sugar management, while Novo Nordisk's drugs target only one pathway, suggesting that retatrutide may offer greater weight loss potential and could become a new favorite in the market.
- Future Market Outlook: With retatrutide's strong efficacy and safety profile, Lilly is poised to apply for regulatory approval in the coming years, further solidifying its market position and potentially delivering high returns for investors as the value of the weight loss drug market continues to rise.
See More
Pfizer Analyst Ratings and Future Outlook
- Divergent Analyst Ratings: MarketWatch tracked 28 ratings for Pfizer (PFE), with 9 analysts recommending a 'buy', 1 suggesting overweight, 15 advising 'hold', and 3 indicating 'sell', indicating a consensus to hold the stock.
- Price Target Increase: Guggenheim Securities reaffirmed its buy rating for Pfizer with a price target of $36 per share, which is 38% higher than the current share price of about $26, reflecting analysts' optimistic outlook on Pfizer's future performance.
- Pipeline Potential: Pfizer has 96 drugs in development, with 31 in late-stage phase 3 trials; analyst Vamil Divan expressed optimism about encouraging results from late-stage trials, predicting a potential upside of about $2 per share if successful.
- Strong Financial Performance: Pfizer's first-quarter report indicated a 22% year-over-year operational revenue growth, with CFO David Denton expressing satisfaction, while CEO Albert Bourla highlighted positive advancements in oncology and obesity within the R&D pipeline, showcasing the company's future growth potential.
See More
Eli Lilly's Breakthrough Weight Loss Drug Trial Success
- Market Share Leadership: Eli Lilly has captured a 60% share of the U.S. GLP-1 market, surpassing early leader Novo Nordisk by launching the dual agonist tirzepatide (Mounjaro and Zepbound), demonstrating its competitive edge in the rapidly growing weight loss drug sector.
- Clinical Trial Success: Lilly's new candidate retatrutide showed remarkable results in a phase 3 trial, with patients losing an average of 28% of their body weight over 80 weeks, and over 30% of participants losing more than 30%, indicating its potential as a more effective weight loss solution compared to existing products.
- Safety and Compliance: The lowest dose of retatrutide had a discontinuation rate of 4.1%, lower than the placebo rate of 4.9%, suggesting that its side effects align with those of current GLP-1 drugs, which may enhance patient adherence and strengthen market competitiveness.
- Future Market Potential: With the weight loss drug market projected to reach $100 billion in the next decade, this breakthrough medication positions Eli Lilly to potentially deliver another blockbuster product, further solidifying its leadership in the field and generating high returns for investors.
See More
